CHMP recommends Tresiba for children/adolescents with Diabetes- Novo Nordisk
Novo Nordisk has announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba (insulin degludec) in children and adolescents aged 1-17 years with Diabetes. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Tresiba to children with type 1 and type 2 Diabetes. According to the International Diabetes Federation, an estimated 497,100 children are living globally with type 1 Diabetes and rates of type 2 Diabetes among children are also on the increase.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.